Impaired T Cell Function in RANTES-Deficient Mice

doi:10.1006/clim.2001.5178

Clinical Immunology

Volume 102, Issue 3, March 2002, Pages 302-309

https://doi.org/10.1006/clim.2001.5178 Get rights and content

Abstract

The chemokine RANTES is a chemoattractant for monocytes and T cells and is postulated to participate in many aspects of the immune response. To evaluate the biological roles of RANTES in vivo, we generated RANTES-deficient (−/−) mice and characterized their T cell function. In cutaneous delayed-type hypersensitivity assays, a 50% reduction in ear and footpad swelling was seen in −/− mice compared to +/+ mice. In vitro, polyclonal and antigen-specific T cell proliferation was decreased. Quantitative analysis using the fluorescent dye carboxy-fluorescein succinimidyl ester revealed that this proliferative defect was due both to fewer antigen-reactive T cells and to a reduction in the capacity of these cells to proliferate. In addition, IFN-γ and IL-2 production by the −/− T cells was dramatically decreased. Together, these data suggest that RANTES is required for normal T cell functions as well as for recruiting monocytes and T cells to sites of inflammation.

References (42)

B.J. Rollins
Chemokines
Blood
(1997)
T.J. Schall
Biology of the Rantes/SIS cytokine family
Cytokine
(1991)
P. Rathanaswami et al.
Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts
J. Biol. Chem.
(1993)
G. Wolf et al.
TNF alpha induces expression of the chemoattractant cytokine RANTES in cultured mouse mesangial cells
Kidney Int.
(1993)
P. Heeger et al.
Isolation and characterization of cDNA from renal tubular epithelium encoding murine RANTES
Kidney Int.
(1992)
I. von Luettichau et al.
RANTES chemokine expression in diseased and normal human tissues
Cytokine
(1996)
L. Petersen et al.
Histamine release in intact human skin by monocyte chemoattractant factor-1, RANTES, macrophage inflammatory protein-1 alpha, stem cell factor, anti-IgE, and codeine as determined by an ex vivo skin microdialysis technique
J. Allergy Clin. Immunol.
(1996)
M. Baggiolini
Chemokines and leukocyte traffic
Nature
(1998)
A.D. Luster
Chemokines—Chemotactic cytokines that mediate inflammation
N. Engl. J. Med.
(1998)
D.N. Cook et al.
Requirement of MIP-1 alpha for an inflammatory response to viral infection
Science
(1995)

B. Lu et al.

Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice

J. Exp. Med.

(1998)

T.J. Schall et al.

A human T cell-specific molecule is a member of a new gene family

J. Immunol.

(1988)

T.M. Danoff et al.

Cloning, genomic organization, and chromosomal localization of the Scya5 gene encoding the murine chemokine RANTES

J. Immunol.

(1994)

A. Verani et al.

C-C chemokines released by lipopolysaccharide (LPS)-stimulated human macrophages suppress HIV-1 infection in both macrophages and T cells

J. Exp. Med.

(1997)

A. Marfaing-Koka et al.

Regulation of the production of the RANTES chemokine by endothelial cells. Synergistic induction by IFN-gamma plus TNF-alpha and inhibition by IL-4 and IL-13

J. Immunol.

(1995)

Y. Kameyoshi et al.

Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils

J. Exp. Med.

(1992)

T.J. Schall et al.

Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES

Nature

(1990)

A. Rot et al.

RANTES and macrophage inflammatory protein 1a induce the migration and activation of normal human eosinophil granulocytes

J. Exp. Med.

(1992)

P. Loetscher et al.

Activation of NK cells by CC chemokines: Chemotaxis, Ca²⁺ mobilization, and enzyme release

J. Immunol.

(1996)

M.C. Dieu et al.

Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites

J. Exp. Med.

(1998)

Cited by (104)

Gene-expression profiling of laser-dissected islets and studies in deficient mice reveal chemokines as differential driving force of type 1 diabetes
2024, Journal of Autoimmunity
Although type 1 diabetes (T1D) results from the autoimmune destruction of the insulin-producing β-cells, its treatment is largely restricted to exogenous insulin administration. Only few therapies targeting the autoaggressive immune system have been introduced into clinical practice or are considered in clinical trials. Here, we provide a gene expression profile of the islet microenvironment obtained by laser-dissection microscopy in an inducible mouse model. Thereby, we have identified novel targets for immune intervention. Increased gene expression of most inflammatory proteins was apparent at day 10 after T1D induction and largely paralleled the observed degree of insulitis. We further focused on genes involved in leukocyte migration, including chemokines and their receptors. Besides the critical chemokine CXCL10, we found several other chemokines upregulated locally in temporary or chronic manner. Localization of the chemokine ligand/receptor pairs to the islet microenvironment has been confirmed by RNAscope. Interference with the CXCL16-CXCR6 and CX₃CL1-CX₃CR1 axes, but not the CCL5-CCR1/3/5 axis, resulted in reduced insulitis and lower T1D incidence. Further, we found that the receptors for the differentially expressed chemokines CXCL10, CXCL16 and CX₃CL1 are distributed unevenly among islet autoantigen-specific T cells, which explains why the interference with just one chemokine axis cannot completely abrogate insulitis and T1D.
Regulation of key molecules of immunological synapse by T11TS immunotherapy abrogates Cryptococcus neoformans infection in rats
2020, Molecular Immunology
Citation Excerpt :
RANTES is associated with a Th1 immune response (Culley et al., 2006; Schrum et al., 1996). RANTES-deficient mice show impaired T cell function (Makino et al., 2002). Our ELISA studies with RANTES shows that it drastically decreased in the serum of CN infected group (P < 0.0001) in contrast to the N group (Fig. 1C).
Cryptococcus neoformans infects and disseminates in hosts with diminished T cell responses. The immunomodulator T11TS (T11 target structure) had profound potential in glioma as well as C. neoformans infected model for disease amelioration. It is been established by our group that T11TS potentiates Calcineurin-NFAT pathway in T cells of C. neoformans infected rats. We investigated the upstream Immunological Synapse (IS) molecules that are vital for the foundation of initial signals for downstream signaling, differentiation and proliferation in T cells. Improved RANTES level in the T11TS treated groups suggests potential recruitment of T cells. Down-regulation of TCRαβ, CD3ζ, CD2, CD45 and CD28 molecules by cryptococcus were boosted after T11TS therapy. Heightened expression of inhibitory molecule CTLA-4 in cryptococcosis was dampened by T11TS. The decline of MHC I, MHC II and CD80 expression on macrophages by C. neoformans were enhanced by T11TS. The dampening of positive regulators and upsurge of negative regulators of the IS during cryptococcosis was reversed with T11TS therapy resulting in enhanced clearance of fungus from the lungs as envisaged by our histological studies. This preclinical study with T11TS opens a new prospect for potential immunotherapeutic intervention against the devastating C. neoformans infection with positive aspect for the long-term solution and a safer immunotherapeutic regimen.
Profiling cytokine levels in chlorhexidine and EGCG-treated odontoblast-like cells
2018, Dental Materials
Citation Excerpt :
Furthermore, CCL5/RANTES is a member of the CC chemokine family with significant activity toward monocytes and eosinophils [46], shown to be expressed in healthy human pulp [47]. This chemokine is known to upregulate IL-12 [48] and INF-γ [49], both shown here in significantly higher levels after cell treatments in comparison to Ctr group. In Dentistry, the mineral trioxide aggregate was shown to downregulate expression of some cytokines in mouse pulp tissue, including IFN-γ and CCL5/RANTES [50].
To screen the effect of two compounds, chlorhexidine diacetate (CHX) and epigallocatechin-gallate (EGCG), on the levels of cytokines produced by odontoblast-like cells (MDPC-23).
Cells were seeded at 24 h and 48 h with serial dilution of the compounds to determine cell metabolic activity by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (n = 3). Cells with no compound treatment were used as control (Ctr). For the highest equal non-cytotoxic compound dilution tested at 48 h cell treatment, total protein concentration was measured using a Pierce bicinchoninic acid (BCA) assay (n = 3), and expression of 23 cytokines was analyzed using the Bio-Plex cytokine assay (n = 2). Data were analyzed by one-way ANOVA and Tukey’s test (α = 5%).
The MTT assay revealed that at 24 h and 48 h, CHX and EGCG did not reduce cell metabolic activity at concentrations of 2.5–20 μM (CHX) and 2.5–160 μM (EGCG), respectively (p > 0.05). At 48 h, total protein levels were consistent across all groups for 20 μM compound dilution (Ctr: 1.04 mg/mL; CHX: 0.98 mg/mL; and EGCG: 1.06 mg/mL). At 20 μM dilution, both CHX and EGCG significantly increased the secretion of IL-1β, IL-10, IL-12, KC, MIP-1α, IFN-γ and IL-6 (p < 0.05). Treatment with CHX significantly increased secretion of IL-4 and RANTES (p < 0.05). Treatment: with EGCG significantly increased Eotaxin secretion (p < 0.05). Both CHX and EGCG significantly decreased secretion of IL-17 (p < 0.05). GM-CSF and TNF-α did not present significant change in secretion after treatment with either CHX or EGCG (p > 0.05).
Both CHX and EGCG modulate secretion of various inflammatory and anti-inflammatory mediators in odontoblastic cells.
Risk Factors, Treatment, and Immune Dysregulation in Autoimmune Cytopenia after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients
2018, Biology of Blood and Marrow Transplantation
Autoimmune or alloimmune cytopenia (AIC) is a known rare complication of hematopoietic stem cell transplantation (SCT). AIC after SCT is considered difficult to treat and is associated with high morbidity and mortality. In this retrospective study in pediatric patients we evaluated incidence, outcome, potential risk factors, and current treatment strategies. A nested matched case-control study was performed to search for biomarkers associated with AIC. Of 531 consecutive SCTs at our center between 2000 and 2016, 26 were complicated by the development of AIC (cumulative incidence, 5.0%) after a median of 5 months post-SCT. Autoimmune hemolytic anemia was the most common AIC with 12 patients (46%). We identified nonmalignant disease, alemtuzumab serotherapy pre-SCT, and cytomegalovirus (CMV) reactivation as independently associated risk factors. The cytokine profile of patients at the time of AIC diagnosis appeared to skew toward a more pronounced Th 2 response compared with control subjects at the corresponding time point post-SCT. Corticosteroids and intravenous immunoglobulin as first-line treatment or a wait-and-see approach led to resolution of AIC in 35% of cases. Addition of step-up therapies rituximab (n = 15), bortezomib (n = 7), or sirolimus (n = 3) was associated with AIC resolution in 40%, 57%, and 100% of cases, respectively. In summary, we identified CMV reactivation post-SCT as a new clinical risk factor for the development of AIC in children. The cytokine profile during AIC appears to favor a Th 2 response. Rituximab, bortezomib, and sirolimus are promising step-up treatment modalities.
A Liver Capsular Network of Monocyte-Derived Macrophages Restricts Hepatic Dissemination of Intraperitoneal Bacteria by Neutrophil Recruitment
2017, Immunity
The liver is positioned at the interface between two routes traversed by pathogens in disseminating infection. Whereas blood-borne pathogens are efficiently cleared in hepatic sinusoids by Kupffer cells (KCs), it is unknown how the liver prevents dissemination of peritoneal pathogens accessing its outer membrane. We report here that the hepatic capsule harbors a contiguous cellular network of liver-resident macrophages phenotypically distinct from KCs. These liver capsular macrophages (LCMs) were replenished in the steady state from blood monocytes, unlike KCs that are embryonically derived and self-renewing. LCM numbers increased after weaning in a microbiota-dependent process. LCMs sensed peritoneal bacteria and promoted neutrophil recruitment to the capsule, and their specific ablation resulted in decreased neutrophil recruitment and increased intrahepatic bacterial burden. Thus, the liver contains two separate and non-overlapping niches occupied by distinct resident macrophage populations mediating immunosurveillance at these two pathogen entry points to the liver.
Functional role of CCL5/RANTES for HCC progression during chronic liver disease
2017, Journal of Hepatology
Citation Excerpt :
We generated mice carrying the loxP-site-flanked NEMO/IKKγ gene under the control of the Alb/AFP-Cre promotor/enhancer as previously described [15,16,19]. From NEMOΔhepa mice, we generated double knockout animals by crossing NEMOΔhepa with constitutive CCL5 deficient mice defined in a C57BL/6 background and purchased from the Jackson Laboratory (Bar Harbor, ME) [20]. Progression of liver disease was monitored in male mice, ranging from 8 to 52 weeks of age.
During liver inflammation, triggering fibrogenesis and carcinogenesis immune cells play a pivotal role. In the present study we investigated the role of CCL5 in human and in murine models of chronic liver inflammation leading to hepatocellular carcinoma (HCC) development.
CCL5 expression and its receptors were studied in well-defined patients with chronic liver disease (CLD) and in two murine inflammation based HCC models. The role of CCL5 in inflammation, fibrosis, tumor initiation and progression was analyzed in different cell populations of NEMO^Δhepa/CCL5^−/− animals and after bone marrow transplantation (BMT). For therapeutic intervention Evasin-4 was injected for 24 h or 8 weeks.
In CLD patients, CCL5 and its receptor CCR5 are overexpressed – an observation confirmed in the Mdr2^−/− and NEMO^Δhepa model. CCL5 deletion in NEMO^Δhepa mice diminished hepatocyte apoptosis, compensatory proliferation and fibrogenesis due to reduced immune cell infiltration. Especially, CD45⁺/Ly6G⁺ granulocytes, CD45⁺/CD11b⁺/Gr1.1⁺/F4/80⁺ pro-inflammatory monocytes, CD4⁺ and CD8⁺ T cells were decreased. One year old NEMO^Δhepa/CCL5^−/− mice displayed smaller and less malignant tumors, characterized by reduced proliferative capacity and less pronounced angiogenesis. We identified hematopoietic cells as the main source of CCL5, while CCL5 deficiency did not sensitise NEMO^Δhepa hepatocytes towards TNFα induced apoptosis. Finally, therapeutic intervention with Evasin-4 over a period of 8 weeks ameliorated liver disease progression.
We identified an important role of CCL5 in human and functionally in mice with disease progression, especially HCC development. A novel approach to inhibit CCL5 in vivo thus appears encouraging for patients with CLD.
Our present study identifies the essential role of the chemoattractive cytokine CCL5 for liver disease progression and especially hepatocellular carcinoma development in men and mice. Finally, the inhibition of CCL5 appears to be encouraging for therapy of human chronic liver disease.

View all citing articles on Scopus

¹: To whom correspondence and reprint requests should be addressed at Department of Molecular Immunology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan. Fax: +81-43-227-1498. E-mail: [email protected].

View full text

Regular ArticleImpaired T Cell Function in RANTES-Deficient Mice

Abstract

Blood

Cytokine

J. Biol. Chem.

Kidney Int.

Kidney Int.

Cytokine

J. Allergy Clin. Immunol.

Chemokines and leukocyte traffic

Nature

Chemokines—Chemotactic cytokines that mediate inflammation

N. Engl. J. Med.

Requirement of MIP-1 alpha for an inflammatory response to viral infection

Science

Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice

J. Exp. Med.

A human T cell-specific molecule is a member of a new gene family

J. Immunol.

Cloning, genomic organization, and chromosomal localization of the Scya5 gene encoding the murine chemokine RANTES

J. Immunol.

C-C chemokines released by lipopolysaccharide (LPS)-stimulated human macrophages suppress HIV-1 infection in both macrophages and T cells

J. Exp. Med.

Regulation of the production of the RANTES chemokine by endothelial cells. Synergistic induction by IFN-gamma plus TNF-alpha and inhibition by IL-4 and IL-13

J. Immunol.

Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils

J. Exp. Med.

Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES

Nature

RANTES and macrophage inflammatory protein 1a induce the migration and activation of normal human eosinophil granulocytes

J. Exp. Med.

Activation of NK cells by CC chemokines: Chemotaxis, Ca2+ mobilization, and enzyme release

J. Immunol.

Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites

J. Exp. Med.

Regular Article
Impaired T Cell Function in RANTES-Deficient Mice

Activation of NK cells by CC chemokines: Chemotaxis, Ca²⁺ mobilization, and enzyme release